

Laura Cristoferi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2321012/publications.pdf>

Version: 2024-02-01

44
papers

638
citations

623734

14
h-index

642732

23
g-index

47
all docs

47
docs citations

47
times ranked

821
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	3.9	26
2	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	3.9	7
3	An update on novel pharmacological agents for primary sclerosing cholangitis. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 69-77.	3.4	5
4	X marks the spot in autoimmunity. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 429-437.	3.0	0
5	The Role of Epigenetics in Primary Biliary Cholangitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4873.	4.1	11
6	Systematic review of pancreatic involvement in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1478-1491.	3.7	18
7	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
8	Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100124.	4.0	0
9	Elastography in Autoimmune Liver Diseases. , 2021, , 91-103.		0
10	Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. <i>Liver International</i> , 2021, 41, 432-435.	3.9	4
11	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	4.9	33
12	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Na ⁺ -ve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , 2021, 74, 1496-1508.	7.3	28
13	Transient elastography in chronic liver disease: Beware of the cut-offs!. <i>Journal of Hepatology</i> , 2021, 75, 1245-1246.	3.7	3
14	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021, 73, 2099-2109.	7.3	56
15	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	1.3	27
16	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100081.	4.0	7
17	PTU-46...Safety and efficacy of fully covered metallic stent placement for patients with primary sclerosing cholangitis. , 2021, , .		0
18	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. <i>Annals of Hepatology</i> , 2020, 19, 5-16.	1.5	13

#	ARTICLE	IF	CITATIONS
19	Individualizing Care. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 87-103.	1.5	0
20	Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. <i>Journal of Hepatology</i> , 2020, 73, 965-966.	3.7	14
21	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. <i>Hepatology Communications</i> , 2020, 4, 1257-1262.	4.3	55
22	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e138-e139.	1.9	8
23	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3095.	2.6	17
24	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. <i>Journal of Autoimmunity</i> , 2020, 113, 102503.	6.5	5
25	Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis". <i>Disease Markers</i> , 2020, 2020, 1-2.	1.3	1
26	Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group. <i>Digestive and Liver Disease</i> , 2020, 52, e32.	0.9	2
27	New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , 2020, 7, 117.	2.6	22
28	Risk stratification in primary sclerosing cholangitis. <i>Minerva Gastroenterology</i> , 2020, , .	0.5	2
29	THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e165.	3.7	0
30	FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study. <i>Journal of Hepatology</i> , 2019, 70, e386.	3.7	0
31	Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2019, 51, e18.	0.9	0
32	Precision medicine in primary biliary cholangitis. <i>Journal of Digestive Diseases</i> , 2019, 20, 338-345.	1.5	9
33	FRI-011-Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e387-e388.	3.7	0
34	Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2019, 51, e1.	0.9	0
35	A Smooth Esophageal Stricture Causing Dysphagia. <i>Dysphagia</i> , 2018, 33, 399-402.	1.8	3
36	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	3.8	3

#	ARTICLE	IF	CITATIONS
37	Prognostic models in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018, 95, 171-178.	6.5	22
38	The immunobiology of female predominance in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018, 95, 124-132.	6.5	24
39	Geoeidemiology and (epi-)genetics in primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 11-15.	2.4	8
40	Individualizing Care. <i>Clinics in Liver Disease</i> , 2018, 22, 545-561.	2.1	3
41	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
42	Prevalence of upper gastrointestinal endoscopic findings in the community: A systematic review of studies in unselected samples of subjects. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1527-1538.	2.8	30
43	Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. <i>Digestive Diseases</i> , 2015, 33, 140-148.	1.9	36
44	Antioxidant Treatment for Acute Pancreatitis. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2014, 8, 154-161.	3.6	0